<DOC>
	<DOCNO>NCT00968006</DOCNO>
	<brief_summary>Endothelial progenitor cell ( EPCs ) involve cardiovascular homeostasis , angiogenesis endothelial healing . Diabetic patient high risk cardiovascular event low level circulate EPCs . Sitagliptin oral DPP-IV antagonist , approve treatment type 2 diabetes . It increase bioavailability endogenous incretins , thus improve insulin glucagon secretion . SDF-1 , one major EPC regulator , also substrate DPP-IV . This study test hypothesis sitagliptin increase level circulate EPCs type 2 diabetic patient .</brief_summary>
	<brief_title>Effect Sitagliptin Endothelial Progenitor Cells</brief_title>
	<detailed_description>Diabetic patient suffer elevated wirk cardiovascular event , strongly impact morbidity mortality . The mechanisms lead cardiovascular disease diabetes include alteration endothelial layer , due hyperglycemia , oxidative stress associate abnormality . Endothelial progenitor cell ( EPCs ) bone marrow-derived cell involve endothelial repair injury , find reduce diabetic patient . Thus , reduce EPCs diabetes may another mechanism vascular disease induction . Reduction EPCs diabetes attributable least part impairment bone marrow mobilization , regulate chemokine SDF-1alpha , among others . The oral hypoglycemia agent sitagliptin dipeptidyl dipeptidase-IV inhibitor , prevents degradation endogenous incretins ( GIP GLP-1 ) , thus re-equilibrating insulin glucagon secretion . Sitagliptin may also increase concentration SDF-1alpha , another substrate DPP-IV . The hypothesis sitagliptin may increase circulate EPC level , SDF-alpha . This go pilot , non-randomized control 4-week trial 100 mg oral sitagliptin therapy add metformin/sulphonylureas poorly control type 2 diabetic patient . At baseline 4 week initiation therapy blood sample draw determination circulate EPC level , concentration SDF-1alpha . EPCs define CD34+KDR+ cell measure flow cytometry previously describe detail . SDF-1alpha measure use ELISA kit accord manufacturer 's instruction . Changes baseline 4 week evaluate use two-tailed paired Student 's test statistical significance accept p &lt; 0.05 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes ; Both gender Age 4080 fast cpeptide &gt; =1.0 ng/L Therapy metformin sulphonylureas HbA1c &gt; 7.0 % No contraindication sitagliptin use Type 1 diabetes Age &lt; 40 &gt; 80 fast cpeptide &lt; 1.0 ng/L Therapy TZD HbA1c &lt; =7.0 % Acute concomitant diseases Immunological disorder Recent ( within 3 month ) cardiovascular event surgery Pregnancy lactation Inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>diabetes</keyword>
	<keyword>endothelium</keyword>
	<keyword>stem cell</keyword>
</DOC>